Stay updated on Pembrolizumab + Imprime PGG in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab + Imprime PGG in NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab + Imprime PGG in NSCLC Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe page now displays Revision: v3.4.2 (replacing Revision: v3.4.1). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check20 days agoChange DetectedRevision label changed from v3.4.0 to v3.4.1 on the page; no changes to study content or functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check27 days agoChange DetectedIntroduced a glossary toggle and updated metadata labels (Last Update Submitted that Met QC Criteria, No FEAR Act Data, Revision: v3.4.0). The older lowercase labels and previous revision tag (Last Update Submitted that met QC Criteria, No FEAR Act data, Revision: v3.3.4) were removed.SummaryDifference0.2%

- Check35 days agoChange DetectedAdded new update dates (2026-01-20, 2025-12-30, 2025-12) and removed older update dates (2024-08-13, 2024-07-18, 2024-07) from the study record history. These are administrative metadata updates that do not modify the study content or outcomes.SummaryDifference0.2%

- Check42 days agoChange DetectedThe study documents page now shows Revision: v3.3.4 and removes Revision: v3.3.3.SummaryDifference0.0%

- Check63 days agoChange DetectedA consolidated Locations section listing study sites by state (Illinois, Indiana, Iowa, New Jersey, Pennsylvania) has been added, and the per-state location blocks have been removed; the revision is updated to v3.3.3.SummaryDifference0.6%

Stay in the know with updates to Pembrolizumab + Imprime PGG in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Imprime PGG in NSCLC Clinical Trial page.